

Special Issue

Oxidative Stress and Proteinopathy in Alzheimer's Disease

Message from the Guest Editor

The multifactorial nature of Alzheimer's disease (AD) has given rise to several research debates on the early events that led to AD. Of note, interrogation of post-mortem AD brain and several neuroimaging studies has revealed accumulation and misfolding of certain proteins (prominantly amyloid beta and tau) as the important primary event playing a significant role in the initiation and progression of the disease. This is of particular relevance since this results in synaptic dysfunction and loss, leading to cognitive decline and ultimately results in neuronal cell death. An intriguing and complex relationship has been shown between A β and mitochondrial dysfunction, redox metal imbalance, failure of protein clearance mechanism, advanced glycation end-products, and calcium excitotoxicity that may further contribute to the oxidative stress in the brains of AD patients. Understanding these interactions may thus aid in the identification of potential neuroprotective therapies that could be clinically useful.

Guest Editor

Dr. Chanchal Sharma

School of Chemistry, Chemical Engineering and Biotechnology,
Nanyang Technological University, Singapore, Singapore

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/186120

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).